COPD's early origins in low-and-middle income countries

FRESH AIR Collaborators; Brakema, E. A.; van Gemert, F. A.; van der Kleij, R. M. J. J.; Salvi, S.; Puhan, M.; Chavannes, N. H.; Pham Le An, Thong; Anastasaki, Marilena; Akmatalieva, Meerim

Published in:
npj Primary Care Respiratory Medicine

DOI:
10.1038/s41533-019-0117-y

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
FRESH AIR Collaborators (2019). COPD's early origins in low-and-middle income countries: what are the implications of a false start? npj Primary Care Respiratory Medicine, 29, [6]. https://doi.org/10.1038/s41533-019-0117-y

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
COPD’s early origins in low-and-middle income countries: what are the implications of a false start?


The Global Initiative for chronic Obstructive Lung disease (GOLD) guideline of 2018 describes COPD as ‘the result of a complex interplay of long-term cumulative exposure to noxious gases and particles, combined with a variety of host factors including genetics, airway hyper-responsiveness and poor lung growth during childhood’. Tobacco smoking is traditionally viewed as the main contributing factor to the development of COPD. However, COPD also occurs among non-smokers, especially in low-income and middle-income countries (LMICs). Notably, more than 90% of COPD-related deaths occur in LMICs. For these countries, other risk factors, such as ambient, occupational and household air pollution play a significant role in the development of COPD.

Does COPD in these settings have a different pathophysiological trajectory compared to COPD in high-income countries, and if so: what does this imply?

In normal lung development, airway branching is completed by the 17th week of gestation, after which airways increase in volume until young adulthood. Alveoli are present at birth and develop further during childhood. Lung volume and airflow continue to increase as the thorax grows, influenced by age, sex, and ethnicity, reaching a peak at young adulthood. Lung function then remains constant for about 10 years (the plateau phase), after which it gradually declines.

In the ‘classic’ COPD patient, the decline in lung function is more rapid than in healthy individuals. However, in a considerable proportion of COPD patients, lung function does not decline rapidly, but reaches a lower plateau phase in early adulthood instead. For these patients, a completely different pathophysiological trajectory seems to lead to the diagnosis of COPD: the decline in lung function follows a normal pattern, yet they seem to have a ‘false start’ by attaining a lower maximum lung function.

Several factors can contribute to a lower maximum lung function. There is increasing evidence that different environmental factors (such as tobacco smoke, household air pollution caused by burning solid fuels or kerosene lamps), maternal factors (malnutrition, asthma, diabetes), and gene–environment interactions can impact lung growth. Additionally, childhood factors (low birth weight, prematurity) and other diseases during childhood (lower respiratory tract infections, asthma, tuberculosis, HIV) may all contribute to a decline in lung function. (Mal) nutrition additionally plays a vital role in lung development. Unfortunately, many of these factors commonly interrelate and co-occur in LMICs. A low socioeconomic status can furthermore deteriorate the situation, as this is not only independently associated with a lower lung function, but also with other health risks (poor access to healthcare, poor nutrition, low birth weight, exposure to indoor and outdoor pollution, poor living conditions and water supply/sanitation). Overall, populations in LMICs are particularly vulnerable to such risk factors for a lower maximum lung function.

Our knowledge about reduced maximum attained lung functions caused by ‘early life disadvantage factors’ in LMICs seems humble compared to the knowledge generated by extensive research on tobacco-related COPD, often conducted in high-income countries. The question is whether these early life, disadvantageous factors cause different COPD phenotypes with their own pathophysiology, diagnostic approach, rate of lung function decline, response to treatment, and potential reversibility. The paucity of data indicates differences may exist, and that those with a lower forced expiratory volume in one second in early adulthood are also exposed to an increased prevalence and earlier incidence of other non-communicable diseases and premature death. Additionally, COPD related to biomass fuel smoke was demonstrated to be commonly present among young, non-smoking women, whereas ‘classic’ COPD patients are elderly, smoking men. Such difference could be attributed to differences in risk exposure between men and women, yet potential differences in sensitivity to COPD between men and women per phenotype could play an additional role. Furthermore, as rates of lung function decline vary according to different COPD phenotypes, sex and race, and other demographic factors such as age and smoking, the rate of decline in patients with a lower plateau phase seems harder to influence.

COPD caused by a false start has several implications. First, COPD caused by early life disadvantage factors should be tackled at much earlier stages. Prevention is key, and must start before birth, continue throughout childhood and then be combined with the ‘regular’ preventive measures targeting an accelerated decline. As early life disadvantage factors are diverse, prevention addressing these factors should be equally diverse. We argue that raising awareness on COPD is therefore crucial. COPD, the third cause of death worldwide, is often completely unknown to local community members, including their healthcare professionals and policymakers. Local curricula for healthcare professionals (doctors,
nurses, midwives) thus need to increase focus on COPD and on its early origin. Moreover, community health workers should be trained on a national scale to facilitate COPD awareness programmes in their communities. Raising awareness among policy makers is also essential. The diverse early life risk factors require COPD interventions to be embedded in a wide, inter-sectoral approach to facilitate a socioeconomic upliftment (targeting amongst others poverty, education, infrastructure, health literacy).

Increased awareness on the early development of COPD and on the existence of COPD in general could enhance early diagnosis and timely action. Increased awareness is particularly important considering the widescale underdiagnosis of COPD. This raises the question how to best diagnose the disease (affordably, easy to learn), and how to do so at an early stage. Although affordable medications to treat COPD in LMICs are rare, non-pharmacological approaches, such as pulmonary rehabilitation and patient education can impact COPD symptoms and disease progression. Particularly in LMICs, these approaches seem cost-effective (if not, cost-saving).24

The second implication is related to research. As outlined earlier, more research into a lower maximum lung function and its clinical implications is needed. Furthermore, a false start implies a different perspective on how to study the effect of interventions targeting household air pollution on lung function. For decades, clean cook stoves programmes fail to demonstrate consistent positive effects on lung function.25 Often this is attributed to flawed implementation of such interventions, or to cross-contamination of air pollution within the community. However, even after successful adoption of clean cook stoves, the lungs in this generation could remain irreversibly damaged. Instead, should we not measure effects on lung function among children and adolescents, or even among the next (unborn) generation?

To conclude, COPD development generally starts early in life due to a complex interplay of disadvantageous factors. Many of these factors particularly occur in LMICs. To address the silent growing epidemic of COPD in LMICs, lung health should be optimised even before birth and in early childhood. Prevention is key, and focus should be on creating large-scale awareness—beyond the healthcare system only, involving all stakeholders. More research is needed to explore the implications of early life disadvantage factors for COPD in LMICs. This should lead to an evidence-based approach for those with a false start—those (at risk of) having a lower maximum lung function.

**FRESH AIR COLLABORATORS**

Pham Le An9, Marilena Anastasakos6, Meerim Akmatalieva7, Azamat Akyldaev7, Andy Barton8, Antonios Bertisias7, Pham Duong Uyen Binh5, Job F. M. van Boven9, Dennis Burgers10, Lucy Cartwright4, Vasiliki E. Chatzea10, Liza Cragg11, Tran Ngoc Dang12, Ilyas Dautov7, Berik Emilov7, Irene Ferarrio12, Ben Hedrick12, Le Huynh Thi Cam Hong5, Nick Hopkins13, Elvira Isavea14, Rupert Jones15, Corona de Jong16, Sanne van Kampen17, Winceslaus Katagira14, Bruce Krenga18, Jesper Kjærgaard15,16, Janwillem Kocks7, Le Thi Tuyet Lan19, Tran Thanh Duy Linh20, Christos Lioni5, Kim Xuan Loan21, Maamed Mademilov7, Andy McEwen17, Patrick Musinguzi14, Rebecca Nantanda14, Grace Ndezi14, Sophia Papadaki14, Hilary Pinnock11,18, Jillian Pooler8, Charlotte Poot1,13, Maarten J. Postma9, Anja Poulsen16, Pippa Powell12, Nguyen Nhat Quynh5, Susanne Plys22, E. A. Brakema et al.

1University of Medicine and Pharmacy, Bishkek, Kyrgyzstan; 2Faculty of Medicine and Dentistry, University of Plymouth, Plymouth, UK; 3University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 4Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; 5International Primary Care Respiratory Group, London, UK; 6European Lung Foundation, Sheffield, UK; 7Imperial College London, London, UK; 8Makerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda; 9The Research Unit for General Practice and Section of General Practice, Department of Public Health, Copenhagen University, Copenhagen, Denmark; 10Global Health Unit, The Department of Paediatrics and Adolescent Health, Juliane Marie Center, Copenhagen University Hospital “Righospitalet”, Copenhagen, Denmark; 11National Centre for Smoking Cessation and Training, Dorchester, UK; 12University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK; 13Coventry University, Coventry, UK and 14University of Minho, School of Medicine, Braga, Portugal

**AUTHOR CONTRIBUTIONS**

E.A. Brakema wrote the first version and subsequent versions of this manuscript in close collaboration with F.v.G. R.v.d.K., M.P., S.S., and N.C. gave input throughout the entire process.

**ADDITIONAL INFORMATION**

Competing interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**REFERENCES**


